
## Erkka SyvĤlahti

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10394603/publications.pdf Version: 2024-02-01



Ερκκά Ονιλάσλητι

#	Article	IF	CITATIONS
1	Depressive symptoms and presynaptic dopamine function in neuroleptic-naive schizophrenia. Schizophrenia Research, 1999, 35, 41-50.	2.0	239
2	Striatal D2 dopamine receptor binding characteristics in vivo in patients with alcohol dependence. Psychopharmacology, 1994, 116, 285-290.	3.1	235
3	Decrease in Human Striatal Dopamine D <sub>2</sub> Receptor Density with Age: A PET Study with [ <sup>11</sup> C]Raclopride. Journal of Cerebral Blood Flow and Metabolism, 1993, 13, 310-314.	4.3	186
4	Sex differences in striatal presynaptic dopamine synthesis capacity in healthy subjects. Biological Psychiatry, 2002, 52, 759-763.	1.3	181
5	The A1 allele of the human D2 dopamine receptor gene is associated with increased activity of striatal L-amino acid decarboxylase in healthy subjects. Pharmacogenetics and Genomics, 2005, 15, 387-391.	1.5	139
6	Clozapine and N-desmethylclozapine are potent 5-HT1C receptor antagonists. European Journal of Pharmacology, 1993, 245, 179-182.	2.6	121
7	Personality Traits and Striatal Dopamine Synthesis Capacity in Healthy Subjects. American Journal of Psychiatry, 2003, 160, 904-910.	7.2	104
8	Decreased striatal dopamine transporter binding in vivo in chronic schizophrenia. Schizophrenia Research, 2001, 52, 115-120.	2.0	102
9	Cortical glutamate–dopamine interaction and ketamine-induced psychotic symptoms in man. Psychopharmacology, 2005, 182, 375-383.	3.1	81
10	The amygdala and schizophrenia: a volumetric magnetic resonance imaging study in first-episode, neuroleptic-naive patients. Biological Psychiatry, 2003, 54, 1302-1304.	1.3	76
11	A volumetric MRI study of the entorhinal cortex in first episode neuroleptic-naive schizophrenia. Biological Psychiatry, 2002, 51, 1005-1007.	1.3	71
12	Ketamine does not decrease striatal dopamine D 2 receptor binding in man. Psychopharmacology, 2002, 164, 401-406.	3.1	65
13	Effect of smoking on neuroleptics in schizophrenia. Schizophrenia Research, 1997, 23, 55-60.	2.0	64
14	Lack of association between the functional variant of the catechol-o-methyltransferase (COMT) gene and early-onset alcoholism associated with severe antisocial behavior. American Journal of Medical Genetics Part A, 2000, 96, 348-352.	2.4	60
15	Dopamine in Schizophrenia. Annals of Medicine, 1996, 28, 557-561.	3.8	51
16	Measurement of extrastriatal D2-like receptor binding with [11C]FLB 457 – a test-retest analysis. European Journal of Nuclear Medicine and Molecular Imaging, 2000, 27, 1666-1673.	6.4	50
17	The effects of amitriptyline, citalopram and reboxetine on autonomic nervous system. Psychopharmacology, 2001, 154, 343-349.	3.1	40
18	Ethanol administration does not alter dopamine D1 and D2 receptor characteristics in rat brain. Neuroscience Letters, 1990, 108, 289-294.	2.1	39

Εκκκά δυνλέφαητι

#	Article	IF	CITATIONS
19	Integrated Treatment Model for First-Contact Patients with a Schizophrenia-Type Psychosis: The Finnish API Project. Nordic Journal of Psychiatry, 1996, 50, 281-287.	1.3	34
20	Receptor binding profile and anxiolytic-type activity of deramciclane (EGIS-3886) in animal models. Drug Development Research, 1997, 40, 333-348.	2.9	34
21	Sertindole is a serotonin 5-HT 2c inverse agonist and decreases agonist but not antagonist binding to 5-HT 2c receptors after chronic treatment. Psychopharmacology, 2001, 157, 180-187.	3.1	30
22	Chronic clozapine treatment down-regulates serotonin 5-HT-1c receptors in rat brain. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1992, 16, 727-732.	4.8	23
23	Differential tolerance to cataleptic effects of SCH 23390 and haloperidol after repeated administration. Psychopharmacology, 1989, 98, 472-475.	3.1	18
24	5-HT1C receptor-mediated phosphoinositide hydrolysis in the rat choroid plexus after chronic treatment with clozapine. European Journal of Pharmacology, 1994, 255, 91-97.	3.5	17
25	Effects of lorazepam administration on striatal dopamine D 2 receptor binding characteristics in man - a positron emission tomography study. Psychopharmacology, 1997, 132, 361-365.	3.1	16
26	Effects of clozapine metabolites and chronic clozapine treatment on rat brain GABAA receptors. European Journal of Pharmacology, 1996, 314, 319-323.	3.5	14
27	Antagonist Binding Characteristics of the Ser311→Cys Variant of Human Dopamine D2Receptorin Vivoandin Vitro. Biochemical and Biophysical Research Communications, 1997, 232, 143-146.	2.1	13
28	Brain 5-HT 2A receptor occupancy of deramciclane in humans after a single oral administration - a positron emission tomography study. Psychopharmacology, 1999, 145, 76-81.	3.1	10
29	Regulation of serotonin 5-HT2C receptors in the rat choroid plexus after acute clozapine treatment. European Journal of Pharmacology, 1994, 269, 201-208.	2.6	9
30	The effects of lorazepam on extrastriatal dopamine D2/3-receptors—A double-blind randomized placebo-controlled PET study. Psychiatry Research - Neuroimaging, 2009, 174, 130-137.	1.8	9
31	Citalopram, a specific inhibitor of serotonin reuptake in treatment of psychotic and borderline patients. Nordic Journal of Psychiatry, 1992, 46, 181-187.	1.3	6
32	Chronic D1-receptor blockade: effects on D2-receptor agonist-induced yawning in rats. Journal of Pharmacy and Pharmacology, 2011, 43, 278-279.	2.4	2
33	Effects of the atypical antidopaminergic drug, metoclopramide and the selective antimuscarinic drug, pirenzepine on neurotransmission. Nordic Journal of Psychiatry, 1987, 41, 491-495.	0.1	0